t2dm and multi morbidity polypharmacy - eventszone · pdf filea case study following...
TRANSCRIPT
![Page 1: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/1.jpg)
T2DM and multi‐morbidityPolypharmacy
Prof. Johan Wens, MD, PhD
University of AntwerpDpt. Primary and Interdisciplinary Care
![Page 2: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/2.jpg)
Multi‐morbidity in primary care
2
Adapted: Fortin, Stewart et al; Ann Fam Med 2012 Mar;10(2):142‐51.
![Page 3: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/3.jpg)
Barnett, K, Mercer SW, Norbury M, Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross‐sectional study. Lancet, 2012; 380(9836):37‐43.
![Page 4: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/4.jpg)
Barnett, K, Mercer SW, Norbury M, Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross‐sectional study. Lancet, 2012; 380(9836):37‐43.
![Page 5: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/5.jpg)
5
Barnett, K, Mercer SW, Norbury M, Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross‐sectional study. Lancet, 2012; 380(9836):37‐43.
![Page 6: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/6.jpg)
6
Teljeur C, Smith SM, Paul G, Kelly A, O'Dowd T. Multimorbidity in a cohort of patients with type 2 diabetes. Eur J Gen Pract. 2013 Mar;19(1):17‐22. doi: 10.3109/13814788.2012.714768.
Network diagram of most common chronic condition pairs in cohort T2DM
![Page 7: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/7.jpg)
Fig 1 Proportion of people with three index conditions who have each of other conditions.
Dumbreck S, Flynn A, Nairn, M, et al. Drug‐disease and drug‐drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h949
![Page 8: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/8.jpg)
A case study…
Mrs. A78 year‐old
T2DMprevious MI (still smokes…)osteo‐arthritisCOPDdepression
8
Hughes, L. D., et al. (2013). "Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity." Age Ageing 42(1): 62‐69.
![Page 9: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/9.jpg)
A case study…
Following guidelines:‐ advised 9 self‐care/lifestyle alterations
with others recommended under circumstances
‐ expected to attend 4 ‐ 6 routine GP appointmentsand 8 – 30 psychosocial intervention appointments for depression, smoking cessation, pulmonary rehabilitation
‐ prescribed 11 medications as a minimum‐ 10 other drugs routinely recommended
depending on intermediate outcome control, symptoms and progression of disease
9
Hughes, L. D., et al. (2013). "Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity." Age Ageing 42(1): 62‐69.
![Page 10: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/10.jpg)
A case study…
Following guidelines:‐ advised 9 self‐care/lifestyle alterations
with others recommended under circumstances
‐ expected to attend 4 ‐ 6 routine GP appointmentsand 8 – 30 psychosocial intervention appointments for depression, smoking cessation, pulmonary rehabilitation
‐ prescribed 11 medications as a minimum‐ 10 other drugs routinely recommended
depending on intermediate outcome control, symptoms and progression of disease
10
Hughes, L. D., et al. (2013). "Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity." Age Ageing 42(1): 62‐69.
![Page 11: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/11.jpg)
Fig 2 Potentially serious drug-drug interactions between drugs recommended by clinical guidelines for three index conditions and drugs recommended by each of other 11 other
guidelines.
Dumbreck S, Flynn A, Nairn, M, et al. Drug‐disease and drug‐drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h949
![Page 12: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/12.jpg)
12
Dumbreck S, Flynn A, Nairn, M, et al. Drug‐disease and drug‐drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h949
![Page 13: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/13.jpg)
13
![Page 14: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/14.jpg)
Fig 3 Types of potentially serious harm from drug-drug interactions between drugs recommended by clinical guidelines for three index conditions and drugs recommended by
each of other 11 other guidelines.
Dumbreck S, Flynn A, Nairn, M, et al. Drug‐disease and drug‐drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h949
![Page 15: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/15.jpg)
Medicine management
15
Payne RA, Avery AJ, Duerden M, Saunders CL, Simpson CR, Abel GA. Prevalence of polypharmacy in a Scottish primary care population. Eur J Clin Pharmacol 2014;70:575‐81.
% 4 to 10 medications > 10 medications
overall adults 16,9 4,6
age 60 – 70 28,6 7,4
age ≥ 80 years 51,8 18,6
![Page 16: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/16.jpg)
16
Payne RA, Avery AJ, Duerden M, Saunders CL, Simpson CR, Abel GA. Prevalence of polypharmacy in a Scottish primary care population. Eur J Clin Pharmacol2014;70:575‐81.
![Page 17: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/17.jpg)
17
Payne RA, Avery AJ, Duerden M, Saunders CL, Simpson CR, Abel GA. Prevalence of polypharmacy in a Scottish primary care population. Eur J Clin Pharmacol2014;70:575‐81.
![Page 18: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/18.jpg)
What can we do…?
‐ medication review
18
![Page 19: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/19.jpg)
What can we do…?
19
O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015 Mar;44(2):213‐8. doi: 10.1093/ageing/afu145. Epub 2014 Oct 16.
![Page 20: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/20.jpg)
What can we do…?
‐ medication review‐ from EBM guidelines to “personal management”‐ prioritization
clinical judgementengagement with patient preferences
20
![Page 21: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/21.jpg)
Conclusions
‐ Potentially serious drug‐drug interactions are common‐ Drug‐disease interactions are less common
exception: chronic kidney disease‐ Future guidelines need‐ epidemiological knowledge of index disease + most
common comorbidities (attention CKD)‐ systematic approach regarding potential interactions
21
![Page 22: T2DM and multi morbidity Polypharmacy - eventszone · PDF fileA case study Following guidelines: ‐ advised 9 self‐care/lifestyle alterations with others recommended under circumstances](https://reader034.vdocuments.mx/reader034/viewer/2022051723/5ab958ef7f8b9ac1058dbd43/html5/thumbnails/22.jpg)
Thank you
22